NBE-Therapeutics engages in the development of “next-generation”, antibody drug conjugates (ADCs) with the objective to develop first-in-class ADC product candidates until clinical proof-of-concept in patients.
NBE Therapeutics is part of the Boehringer-Ingelheim group.
Products, services, technology
Antibody Drug Conjugates (ADCs).
Cooperation possibilities
Technology and early ADC development candidate partnering for joint development into the clinic.
- http://www.nbe-therapeutics.com
- +41 77 466 37 36
- Jean Engela
